



The Role of Podocyte Apoptosis and the Involvement of SIRT1 in Diabetic Nephropathy

Iijima K and Kamiyama M*

Department of Food and Nutrition, Jumonji University, 2-1-28, Sugasawa, Niiza, Saitama 352-8510, Japan

*Corresponding author: Masumi Kamiyama, Department of Food and Nutrition, Jumonji University, 2-1-28, Sugasawa, Niiza, Saitama 352-8510, Japan, Tel: +81 48-260-7621; Email: masumi-k@jumonji-u.ac.jp

Mini Review

Volume 11 Issue 1

Received Date: May 19, 2026

Published Date: May 27, 2026

DOI: [10.23880/fsnt-16000367](https://doi.org/10.23880/fsnt-16000367)

Abstract

Diabetic nephropathy is the most common chronic microvascular complication of diabetes and the role of podocytes in diabetic nephropathy has been extensively investigated in recent years. Podocytes, along with endothelial cells and the glomerular basement membrane, are crucial components of the glomerular filtration barrier, and podocyte damage and dysfunction are associated with diabetic nephropathy. In particular, dysfunction of the podocyte foot-like processes, particularly as a result of apoptosis, affects the glomerular filtration rate and causes proteinuria. This mini-review examines the mechanisms of podocyte apoptosis and discusses the latest findings on podocyte-related diabetic nephropathy, particularly the involvement of SIRT1.

Keywords: Podocytes; Apoptosis; Diabetic nephropathy

What is SIRT1?

Six types of sirtuin (SIRT) have been identified [1]. SIRT1s are nicotinamide adenine dinucleotide (NAD⁺)-dependent deacetylators that function as intracellular regulators of transcriptional activity. Under conditions of excessive nutrient supply, when the NAD⁺/NADH ratio decreases, levels of renal SIRT1 are reduced in diabetic patients and experimental models of diabetes. A mouse model with specific Sirt1 knockdown exhibits severe albuminuria and mitochondrial dysfunction, demonstrating the importance of SIRT1 to renal function [2-6]. Therefore, this review focuses on sirt1 and discusses its role in inducing apoptosis in podocytes in diabetic nephropathy.

Food and Diabetic Nephropathy

Yuan, et al. [7] reported that the plant-derived compound diosgenin has a protective effect on podocyte injury in diabetic nephropathy by enhancing podocyte survival, suppressing inflammatory injury, and weakening insulin resistance. They also showed that diosgenin activates the AMPK/SIRT1/NFκB signaling pathway. These findings indicate that diosgenin may suppress diabetic nephropathy.

Puerarin is the active ingredient in Radix puerariae and a major compound used in traditional Chinese medicine used to treat patients with diabetic nephropathy. Li et al. [8] showed that in streptozocin-induced diabetic mice, puerarin protects

podocytes from diabetic damage through the upregulation of HMOX1 and SIRT1-mediated autophagy.

Li, et al. [9] reported effects of the traditional Chinese medicine, baicalin (5,6,7-trihydroxyflavone), using cell-based methods. Baicalin is in the Chinese Pharmacopoeia and is a major flavonoid purified from the roots of *Astragalus membranaceus*. Treatment with baicalin after hyperglycemic stimulation decreased the rate of apoptosis and increased the survival of podocytes. Furthermore, in diabetic nephropathy, the effects of baicalin are associated with the SIRT1/NF κ B signaling pathway.

Chang, et al. [10] investigated the role of Tanshen-Weining formula, a traditional Chinese medicine, using db/db mice, a model of type II diabetes. Apoptosis activity and levels of cleaved caspase-3 were elevated in the kidneys of db/db mice compared with non-diabetic mice and Tanshen-Weining formula suppressed these effects. Podocyte damage in db/db kidneys was reduced by Tanshen-Weining formula. The levels of podocin and nephrin in the kidneys of db/db mice were reduced compared with those in the kidneys of non-diabetic mice, and podocalyxin was increased in the urine of db/db mice compared with non-diabetic mice. After treatment of db/db mice with Tanshen-Weining formula, levels of podocin and nephrin increased in the kidneys and urinary podocalyxin was suppressed. db/db mice had lower SIRT1 levels and higher HIF1 α levels in the kidney compared with non-diabetic mice, but Tanshen-Weining formula promoted SIRT1 and inhibited HIF1 α in the kidneys of db/db mice. Furthermore, SIRT1 levels were reduced in podocytes of db/db mice compared with those in non-diabetic mice and Tanshen-Weining formula normalized this reduction.

Xue, et al. [11] investigated Lou, et al. [12] generated a diabetic nephropathy mouse model by combining streptozotocin with a high-fat diet. The mouse model showed increased levels of fasting blood glucose, glycated hemoglobin, triglycerides, total cholesterol, and inflammatory cytokines, decreased levels of nephrin and podocin, increased rates of apoptosis, and enhanced oxidative stress. Administration of cholagin, an ellagitannin from the Tanninaceae family of medicinal plants, improved all these measures. Furthermore, cholagin increased levels of SIRT1 and AMPK, inhibited reactive oxygen species and oxidative stress, and increased autophagy in hyperglycemia-induced podocytes. These findings indicate that cholagin mitigates podocyte damage by regulating autophagy through the SIRT1-AMPK pathway.

The effect of mogroside IIIIE, a cucurbitan-type compound isolated from *Siraitia grosvenori*, on MPC-5 cells under normal glucose or hyperglycemic conditions. Mogroside IIIIE enhanced the viability of hyperglycemic MPC-5 cells,

and reduced levels of inflammatory cytokines and oxidative stress-related markers. Furthermore, hyperglycemia-induced podocyte apoptosis was inhibited after MG IIIIE intervention: BCL2 levels were upregulated, BAX levels were downregulated, and cleaved caspase 3 and caspase 9 were observed. Mogroside IIIIE also activated AMPK/SIRT1 signaling.

Thus, AMPK/SIRT1 signaling in podocytes is important in the onset and progression of diabetic nephropathy, and suppressing this mechanism appears to be a key factor in the progression of complications from diabetes to nephropathy.

Medicine and Diabetic Nephropathy

Obstruction of the renin-angiotensin II system prevents or delays albuminuria in diabetic patients. Gu et al., [13] investigated the inhibitory mechanism of the angiotensin receptor blocker, olmesartan, on albuminuria in a mouse model of diabetic nephropathy and reported that olmesartan suppressed the increased number of apoptotic cells and decreased the number of podocytes in diabetic glomeruli. Furthermore, *in vitro* studies revealed that olmesartan prevented angiotensin II/p38/SIRT1-induced podocyte apoptosis, while slightly suppressing the prevention of high-glucose/AMPK/SIRT1-induced podocyte apoptosis. This represents a novel mechanism of action for olmesartan.

Zhuang, et al. [14] investigated the mechanism by which metformin, a first-line hypoglycemic agent for the treatment of type 2 diabetes, protects renal podocytes under high-glucose conditions and the association between miR-34a and SIRT1 in diabetic nephropathy. Microarray and RT-qPCR analyses revealed that miR-34a is downregulated in hyperglycemic podocytes, concomitant with decreased cell viability and induction of apoptosis. Metformin administration to hyperglycemic podocytes upregulated miR-34a, suppressed apoptosis, and restored cell viability. A dual luciferase reporter assay showed that the SIRT1 3'-UTR is a direct target of miR-34a. Further studies showed increased levels of SIRT1 in hyperglycemic-exposed podocytes, while metformin treatment decreased SIRT1 levels. Furthermore, upregulation of miR-34a reduced SIRT1 levels, while inhibition of miR-34a increased intracellular SIRT1 levels. These observations indicate that metformin-induced miR-34a suppresses podocyte apoptosis by acting on SIRT1 under hyperglycemic conditions.

Since it has been shown that drugs can also affect the AMPK/SIRT1 mechanism, it is expected that these research findings will be confirmed and applied in the future.

Conclusion

The mechanism of podocyte apoptosis in diabetic nephropathy has been elucidated through animal model and in vitro studies, and the effects of herbal medicines and other drugs on this mechanism are now being investigated. Further investigation and confirmation of results are crucial for the development of these drugs. In addition, well-designed and rigorously controlled clinical trials are essential to evaluate safety, efficacy, and long-term effects of drug candidates in diverse patient populations. Clinical data are indispensable to confirm whether the benefits observed in preclinical models translate to meaningful outcomes in humans. If validated by rigorous clinical evidence, these treatments have the potential to provide novel treatment options.

References

1. Chuang PY, Xu J, Dai Y, Jia F, Mallipattu SK, et al. (2014) In vivo RNA interference models of inducible and reversible Sirt1 knockdown in kidney cells. *Am J Pathol* 184(7): 1940-1956.
2. Li X, Zhang Y, Xing X, Li M, Liu Y, et al. (2023) Podocyte injury of diabetic nephropathy: Novel mechanism discovery and therapeutic prospects. *Biomed Pharmacother* 168: 115670.
3. Ala M (2023) Sestrin2 Signaling Pathway Regulates Podocyte Biology and Protects against Diabetic Nephropathy. *J Diabetes Res* 8776878.
4. Nakatani Y, Inagi R (2016) Epigenetic Regulation Through SIRT1 in Podocytes. *Curr Hypertens Rev* 12(2): 89-94.
5. Wang W, Sun W, Cheng Y, Xu Z, Cai L, et al. (2019) Role of sirtuin-1 in diabetic nephropathy. *J Mol Med (Berl)* 97(3): 291-309.
6. Yasmin F, Tang KS (2025) Potential role of polydatin in treating diabetes mellitus and diabetes-related chronic complications. *Biosci Rep* 45(5): 303-323.
7. Yuan H, Sui H, Li S. (2023) Diosgenin alleviates the inflammatory damage and insulin resistance in high glucose-induced podocyte cells via the AMPK/SIRT1/NF-kappaB signaling pathway. *Exp Ther Med* 25(6): 259.
8. Li J, Ling Y, Yin S, Yang S, Kong M, et al. (2020) Baicalin serves a protective role in diabetic nephropathy through preventing high glucose-induced podocyte apoptosis. *Exp Ther Med* 20(1): 367-374.
9. Li X, Zhu Q, Zheng R, Yan J, Wei M, et al. (2020) Puerarin Attenuates Diabetic Nephropathy by Promoting Autophagy in Podocytes. *Front Physiol* 11: 73.
10. Chang J, Zheng J, Gao X, Dong H, Yu H, et al. (2022) TangShenWeiNing Formula Prevents Diabetic Nephropathy by Protecting Podocytes Through the SIRT1/HIF-1alpha Pathway. *Front Endocrinol (Lausanne)* 2022(13): 888611.
11. Xue W, Mao J, Chen Q, Ling W, Sun Y, et al. (2020) Mogroside IIIE Alleviates High Glucose-Induced Inflammation, Oxidative Stress and Apoptosis of Podocytes by the Activation of AMPK/SIRT1 Signaling Pathway. *Diabetes Metab Syndr Obes* 13: 3821-3830.
12. Lou Y, Luan YT, Rong WQ, Gai Y, et al. (2024) Corilagin alleviates podocyte injury in diabetic nephropathy by regulating autophagy via the SIRT1-AMPK pathway. *World J Diabetes* 15(9): 1916-1931.
13. Gu J, Yang M, Qi N, Mei S, Chen J, et al. (2016) Olmesartan Prevents Microalbuminuria in db/db Diabetic Mice Through Inhibition of Angiotensin II/p38/SIRT1-Induced Podocyte Apoptosis. *Kidney Blood Press Res* 41(6): 848-864.
14. Zhuang X, Sun Z, Du H, Zhou T, Zou J, et al. (2024) Metformin inhibits high glucose-induced apoptosis of renal podocyte through regulating miR-34a/SIRT1 axis. *Immun Inflamm Dis* 12(1): e1053.